Advanced Esophageal Squamous Cell Carcinoma
Conditions
Brief summary
An open-label, multicenter, randomized, phase II clinical trial to evaluate the safety, tolerability and efficacy of SHR-9839(sc) as monotherapy or in combination with chemotherapy plus adebelimab in patients with advanced esophageal squamous cell carcinoma (ESCC).
Interventions
SHR-9839(sc) for Injection，dose level 1
DRUGSHR-9839(sc) for Injection、Adebrelimab Injection、Paclitaxel for Injection、Cisplatin Injecion
Safety run-in Stage: SHR-9839(sc) for Injection ,dose level 1 or lower dose、Adebrelimab Injection、Paclitaxel for Injection、Cisplatin Injecion; Dose extension Stage: SHR-9839(sc) for Injection,dose according to Safety run-in Stage、Adebrelimab Injection、Paclitaxel for Injection、Cisplatin Injecion or Adebrelimab Injection、Paclitaxel for Injection、Cisplatin Injecion
Sponsors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Capable of providing informed consent; has signed and dated the IRB/EC-approved informed consent form, and is willing and able to comply with scheduled study visits, examinations and all other protocol-specified procedures. 2. Aged between 18 and 75 years inclusive at the time of informed consent signature, irrespective of gender. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. Histopathologically confirmed locally advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC). 5. Expected survival ≥12 weeks. 6. Must provide a minimum of 11 formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks or unstained tumor slides. 7. Females of childbearing potential must agree to use adequate effective contraception from the date of informed consent, throughout study treatment, and for 9 months after the last dose of investigational product, and refrain from oocyte donation during this period (refer to subsequent section for detailed contraceptive requirements).
Exclusion criteria
1. Uncontrolled or symptomatic active central nervous system (CNS) metastases without adequate prior treatment. 2. History of another concurrent malignant tumor diagnosed within 3 years prior to the first study drug administration. 3. Presence of uncontrolled tumor-related pain as assessed by the Investigator. 4. Severe cardiovascular or cerebrovascular diseases. 5. History of interstitial lung disease (ILD) including idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans organizing pneumonia), drug-induced pneumonitis, radiation pneumonitis requiring steroid therapy; or suspected/unruled-out ILD on screening imaging; or moderate-to-severe pulmonary disease severely impairing respiratory function. 6. Severe infection within 4 weeks before study treatment initiation, including but not limited to bacteremia, severe pneumonia or other infectious complications requiring hospitalization; active CTCAE Grade ≥2 infection requiring systemic antibiotics within 2 weeks prior to first dose (subjects on prophylactic antibiotics e.g., for urinary tract infection prophylaxis are eligible). 7. History of immunodeficiency including positive HIV serology; active hepatitis B (positive HBsAg at screening plus HBV-DNA ≥2500 copies/mL /500 IU/mL or above local laboratory cutoff); or active hepatitis C (positive anti-HCV plus detectable HCV RNA). 8. Active pulmonary tuberculosis within 1 year before enrollment by medical history or imaging; or prior active pulmonary tuberculosis \>1 year ago without standardized anti-tuberculosis treatment. 9. Toxicities/complications from prior anti-tumor therapies not recovered to NCI-CTCAE Grade ≤1 or levels specified by eligibility criteria; subjects with Grade ≤2 toxicities may enroll if deemed without safety risk by the Investigator. 10. Receipt of any systemic anti-cancer therapy within 4 weeks prior to study treatment start. 11. Thoracic radiotherapy \>30 Gy within 24 weeks, non-thoracic radiotherapy \>30 Gy within 4 weeks before first dose; palliative radiotherapy ≤30 Gy within 14 days before first dose (exception: subjects completing brain metastasis radiotherapy ≥14 days prior to first dose are permitted). For prior radioisotope therapy, a washout of at least five half-lives of the radioisotope is required before study enrollment. 12. Major organ surgery (excluding core needle biopsy) or significant trauma within 4 weeks before first study drug, or planned elective surgery during trial participation; invasive minor surgery (biopsy, endoscopy, drainage procedure) within 7 days prior to first dose. 13. Any other condition judged by the Investigator likely to interfere with trial conduct or subject safety, such as alcohol/drug abuse, uncontrolled severe illness (including psychiatric disorders) requiring concomitant medication, clinically significant abnormal laboratory findings, familial/social issues or other factors compromising subject safety or data integrity.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR：Objective Response Rate | First administration to end of treatment visit about 1year |
Secondary
| Measure | Time frame |
|---|---|
| DOR：Duration of relief | First administration to disease progression about 1 year |
| DCR：Disease Control Rate | First administration to disease progression about 1 year |
| PFS：progression-free survival | First administration to disease progression about 1 year |
| OS：Overall Survival | First administration until participant's death about 2 years |
| DLT：The Dose-Limiting Toxicity | Post-dose at day 1 to Day21 |
| MTD： The Maximum Tolerated Dose | Post-dose at day 1 to Day21 |
| AE：Incidence and severity of adverse events | Sign the informed consent form until Safety follow-up completed about 1 year |
| ADA ：Anti-Drug Antibody | Day1 pre-dose to 30 days after the last dose about 1 year |
Countries
China
Contacts
CONTACTLin Ma
CONTACTCong Wen
Outcome results
None listed